JP2015526696A - プロタンパク質転換酵素スブチリシン／ケキシン９型（ｐｃｓｋ９）阻害に対する高感度の有効性および特異性バイオマーカー - Google Patents

プロタンパク質転換酵素スブチリシン／ケキシン９型（ｐｃｓｋ９）阻害に対する高感度の有効性および特異性バイオマーカー Download PDF

Info

Publication number
JP2015526696A
JP2015526696A JP2015513220A JP2015513220A JP2015526696A JP 2015526696 A JP2015526696 A JP 2015526696A JP 2015513220 A JP2015513220 A JP 2015513220A JP 2015513220 A JP2015513220 A JP 2015513220A JP 2015526696 A JP2015526696 A JP 2015526696A
Authority
JP
Japan
Prior art keywords
cer
glc
galcer
lipid
sphingosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015513220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526696A5 (cg-RX-API-DMAC7.html
Inventor
レイヨ ラークソネン
レイヨ ラークソネン
Original Assignee
ゾラ バイオサイエンシーズ オサケ ユキチュア
ゾラ バイオサイエンシーズ オサケ ユキチュア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾラ バイオサイエンシーズ オサケ ユキチュア, ゾラ バイオサイエンシーズ オサケ ユキチュア filed Critical ゾラ バイオサイエンシーズ オサケ ユキチュア
Publication of JP2015526696A publication Critical patent/JP2015526696A/ja
Publication of JP2015526696A5 publication Critical patent/JP2015526696A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015513220A 2012-05-25 2013-05-24 プロタンパク質転換酵素スブチリシン／ケキシン９型（ｐｃｓｋ９）阻害に対する高感度の有効性および特異性バイオマーカー Pending JP2015526696A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651569P 2012-05-25 2012-05-25
US61/651,569 2012-05-25
EP12169517.5A EP2667197B1 (en) 2012-05-25 2012-05-25 Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
EP12169517.5 2012-05-25
PCT/EP2013/060816 WO2013175016A1 (en) 2012-05-25 2013-05-24 Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibition

Publications (2)

Publication Number Publication Date
JP2015526696A true JP2015526696A (ja) 2015-09-10
JP2015526696A5 JP2015526696A5 (cg-RX-API-DMAC7.html) 2016-11-10

Family

ID=46146755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513220A Pending JP2015526696A (ja) 2012-05-25 2013-05-24 プロタンパク質転換酵素スブチリシン／ケキシン９型（ｐｃｓｋ９）阻害に対する高感度の有効性および特異性バイオマーカー

Country Status (7)

Country Link
US (1) US20160146842A2 (cg-RX-API-DMAC7.html)
EP (1) EP2667197B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015526696A (cg-RX-API-DMAC7.html)
CN (1) CN104508488A (cg-RX-API-DMAC7.html)
CA (1) CA2875419A1 (cg-RX-API-DMAC7.html)
ES (1) ES2552371T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013175016A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2014135696A1 (en) * 2013-03-08 2014-09-12 Zora Biosciences Oy Non-high density lipoprotein derived cvd markers
WO2017097852A2 (en) * 2015-12-07 2017-06-15 Zora Biosciences Oy Use of ceramides and lpls in diagnosing cvd
EP3515950A4 (en) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
CN114062581A (zh) * 2017-12-14 2022-02-18 江苏豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2019119049A1 (en) * 2017-12-20 2019-06-27 Baker Heart and Diabetes Institute Method of predicting drug therapeutic responder status and methods of treatment
CN109504737A (zh) * 2018-11-23 2019-03-22 黄河科技学院 一种体外筛选pcsk9抑制剂的方法
WO2022089486A1 (zh) * 2020-10-28 2022-05-05 江苏柯菲平医药股份有限公司 抑制PCSK9基因表达的siRNA及其修饰物与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138419A1 (en) * 2010-05-05 2011-11-10 Zora Biosciences Oy Lipidomic biomarkers for atherosclerosis and cardiovascular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127192A2 (en) * 2006-04-24 2007-11-08 Duke University Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
CA2658183A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
US20100041102A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
CA2681428A1 (en) * 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
SG2013014352A (en) 2007-10-26 2014-09-26 Merck Sharp & Dohme Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
DE112010004626T5 (de) * 2009-12-01 2012-10-18 Metanomics Health Gmbh Mittel und Verfahren zur Diagnose von multipler Sklerose
EP3502707A1 (en) * 2010-01-29 2019-06-26 metanomics GmbH Means and methods for diagnosing heart failure in a subject
EP2583107A2 (en) * 2010-06-20 2013-04-24 Zora Biosciences OY Lipidomic biomarkers for identification of high-risk coronary artery disease patients
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138419A1 (en) * 2010-05-05 2011-11-10 Zora Biosciences Oy Lipidomic biomarkers for atherosclerosis and cardiovascular disease
JP2013527449A (ja) * 2010-05-05 2013-06-27 ゾラ バイオサイエンシーズ オサケ ユキチュア アテローム性動脈硬化症及び心脈管系疾患のリピドームバイオマーカー

Also Published As

Publication number Publication date
EP2667197A1 (en) 2013-11-27
US20160146842A2 (en) 2016-05-26
CN104508488A (zh) 2015-04-08
CA2875419A1 (en) 2013-11-28
ES2552371T3 (es) 2015-11-27
US20150160247A1 (en) 2015-06-11
WO2013175016A1 (en) 2013-11-28
EP2667197B1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
US10955427B2 (en) Lipidomic biomarkers for identification of high-risk coronary artery disease patients
US20240385201A1 (en) Lipidomic biomarkers for atherosclerosis and cardiovascular disease
JP6388284B2 (ja) スタチン治療を受けている冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー
JP6388283B2 (ja) スタチン治療を受けていない冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー
EP2667197B1 (en) Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171204